Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
News about Amgen Inc. (AMGN) centers on its biotechnology medicines, clinical milestones, corporate transactions and investor communications. The company describes itself as discovering, developing, manufacturing and delivering medicines for cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases, and its news flow reflects activity across these therapeutic areas.
Investors following AMGN news can see updates on regulatory decisions and clinical data for key products. Recent announcements include U.S. Food and Drug Administration approvals and label expansions, such as full approval for IMDELLTRA (tarlatamab-dlle) in extensive stage small cell lung cancer after progression on platinum-based chemotherapy, and approval of UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis who are anti-acetylcholine receptor and anti-MuSK antibody positive. Amgen has also reported landmark cardiovascular outcomes data for Repatha (evolocumab) from the VESALIUS-CV trial.
Corporate development and pipeline news are another focus. Amgen has announced the acquisition of Dark Blue Therapeutics, a biotechnology company developing targeted protein degraders for oncology, adding an investigational MLLT1/3-targeting molecule for acute myeloid leukemia to its portfolio. The company also issues releases on capital allocation decisions, such as dividend declarations, and on participation in major healthcare investment conferences where management discusses business developments.
This AMGN news page allows readers to track company press releases and related coverage, including clinical trial readouts, FDA decisions, acquisitions, pricing and access initiatives, and presentations at scientific and investor meetings. Users interested in biotechnology, oncology innovation, cardiovascular outcomes and large-cap healthcare equities can monitor these updates as part of their ongoing research on Amgen stock.
Amgen (NASDAQ: AMGN) has declared a $1.76 per share dividend for Q3 2021, set to be paid on September 8, 2021, to stockholders of record by August 17, 2021. This action reflects the company's ongoing commitment to returning value to its shareholders. Amgen continues to focus on developing innovative therapeutics to address unmet medical needs and improve patient health outcomes. The company, established in 1980, is recognized as a leader in biotechnology, striving to advance its pipeline of medicines.
Amgen announced the appointment of S. Omar Ishrak to its Board of Directors, effective immediately. Dr. Ishrak, a seasoned leader with extensive experience in the healthcare sector, will also serve on the Corporate Responsibility and Compliance Committee and the Compensation and Management Development Committee. With this addition, Amgen's Board now comprises 12 directors, 11 of whom are independent. Ishrak previously served as CEO of Medtronic and has held pivotal roles at GE Healthcare. His expertise is expected to enhance Amgen's focus on innovation and patient care.
Amgen (NASDAQ:AMGN) will report its Q2 2021 financial results on August 3, 2021, after U.S. market close. A conference call is scheduled for 2:00 p.m. PT, featuring CEO Robert A. Bradway and senior management. The call will be broadcast live and accessible to the media and general public. Amgen, a leader in biotechnology since 1980, focuses on developing therapies for serious illnesses through advanced human genetics, with a commitment to improving health outcomes.
Amgen has announced an agreement to acquire Teneobio for $900 million in upfront cash, with potential future milestone payments of up to $1.6 billion. Teneobio specializes in Human Heavy-Chain Antibodies and its advanced bispecific and multispecific antibody technologies will enhance Amgen's capabilities in treating various diseases. The acquisition adds TNB-585, a Phase 1 bispecific T-cell engager for metastatic prostate cancer, along with several preclinical oncology assets. The deal is expected to close in the second half of 2021, pending regulatory approvals.
Amgen (NASDAQ:AMGN) has partnered with the International Federation of Psoriasis Associations to launch the UPLIFT Innovation Challenge, aimed at improving health outcomes for individuals with psoriatic disease. Applicants can submit innovative ideas by August 30, 2021, for a chance to receive a grant of $25,000 USD. This initiative responds to findings from the 2020 UPLIFT survey, which highlighted significant gaps in treatment and patient-provider communication. Notably, it found only 50% of those with psoriatic arthritis saw a healthcare provider within the past year.
Amgen (NASDAQ:AMGN) announced that the FDA has accepted its Biologics License Application for tezepelumab, granting it Priority Review for asthma treatment. This decision was based on the PATHFINDER clinical trial results, particularly the NAVIGATOR Phase 3 trial, where tezepelumab showed superiority over placebo for patients with uncontrolled asthma. The FDA aims to make a decision by Q1 2022. This innovative treatment addresses a significant unmet medical need, as many patients do not respond well to current therapies.
Amgen (NASDAQ:AMGN) has received marketing approval from the Japanese Ministry of Health, Labour and Welfare for Aimovig® (erenumab), the first treatment in Japan targeting the calcitonin gene-related peptide receptor for migraine prevention in adults. This marks Amgen K.K.'s first independent submission and approval. Aimovig demonstrated a significant reduction in monthly migraine days in clinical trials. With approximately 8.4 million migraine sufferers in Japan, this approval aims to increase access to effective migraine treatment.
deCODE genetics, a subsidiary of Amgen, has developed a blood-based predictor to estimate time to all-cause death, outperforming traditional risk factors. The research analyzed nearly 5,000 protein measurements from 22,913 Icelanders, revealing a significant correlation between protein profiles and mortality. The predictor effectively identifies individuals at both high and low risk of death within a decade. Key findings include the role of growth/differentiation factor 15 (GDF15) in predicting mortality.
Amgen has launched the INSIDE LOOK campaign featuring Hollywood makeup artist Allan Avendaño to raise awareness about plaque psoriasis, a chronic autoimmune condition affecting over 8 million Americans. Avendaño shares his personal journey with the disease, emphasizing the importance of understanding and treating the condition from within. The campaign includes a makeup tutorial for Otezla patients and highlights that Otezla can help achieve up to 75% clearer skin in four months. Dermatologist Dr. Jennifer Soung discusses treatment options and urges individuals to consult healthcare providers for personalized treatment plans.
Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 4:40 p.m. ET. Key executives, including David M. Reese and Peter H. Griffith, will speak at this event. A live audio broadcast of the presentation will be available for the public, and the replay will be accessible for 90 days post-event. Amgen, a leader in biotechnology since 1980, focuses on innovative therapeutics for serious illnesses, leveraging advanced human genetics to improve health outcomes.